抗组织纤维化多肽药物研究进展

组织纤维化是一种慢性疾病,多发于肝、肺、心脏、肾脏等部位,全球有 1/3 的人死于组织纤维化以及由其产生的器官衰竭。当组 织受到损伤后,损伤部位发生一系列细胞反应,最终导致细胞外基质过度沉积,发生组织纤维化。纤维化治疗的策略和药物开发围绕着抑 制纤维化过程中关键细胞通路和蛋白的分泌而展开。在药物开发过程中,多肽药物因其高效性、毒副作用低,可以根据治疗目的进行针对 性设计,成为研究人员进行抗纤维化药物开发的良好选择,现已有部分药物进入临床研究。综述抗纤维化治疗中的多肽药物及其治疗的机制, 为其他相关药物开发提供思路。

Advances in Research on Anti-fibrosis Polypeptide Drugs

Tissue brosis is a chronic disease that often occurs in lung, liver, kidney and heart. One third of all death worldwide is caused by tissue brosis and subsequent organ failure. Chronic tissue injury will cause complex cascades of cellular and molecular responses which results in over- deposition of extracellular matrix and eventually fibrosis. Investigations on key cellular pathways and secreted proteins with inhibitory effects on brosis shed light on new treatment and drugs. Nowadays, more and more researchers focus on polypeptide drugs due to their high ef ciency, low toxicity and tissue-speci c design. Some anti- brosis polypeptide drugs have already entered clinical trials. In this article, polypeptide drugs for brosis treatment and their mechanisms were reviewed, so as to provide some ideas for the development of new drugs.